SHEDIR PHARMA GROUP S.P.A. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 3.9 EUR | 0.00% |
|
-2.01% | -13.72% |
| 06-19 | ITALY GROWTH WINNERS & LOSERS: Comal leads risers; Nusco does well. | AN |
| 04-02 | Shedir Pharma, into 2023 with rising revenues; profit down single digits | AN |
| Sales 2022 | 53.48M 57.7M 4.53B | Sales 2023 | 59.39M 64.08M 5.03B | Capitalization | 51.4M 55.45M 4.35B |
|---|---|---|---|---|---|
| Net income 2022 | 5M 5.39M 423M | Net income 2023 | 5M 5.39M 423M | EV / Sales 2022 | 0.69 x |
| Net cash position 2022 | 5.64M 6.09M 478M | Net Debt 2023 | 7.26M 7.83M 615M | EV / Sales 2023 | 0.99 x |
| P/E ratio 2022 |
7.2
x | P/E ratio 2023 |
9.2
x | Employees | 79 |
| Yield 2022 |
4.69% | Yield 2023 |
-
| Free-Float | 12.01% |
More Fundamentals
* Assessed data
More news
More news
| 1 week | -2.01% | ||
| Current month | -1.02% | ||
| 1 month | -1.02% | ||
| 3 months | +5.41% | ||
| 6 months | -14.47% | ||
| Current year | -13.72% |
1 week
3.88
3.98
1 month
3.724.10
Current year
3.344.68
1 year
3.344.82
3 years
2.705.22
5 years
2.708.80
10 years
2.708.80
| Managers | Title | Age | Since |
|---|---|---|---|
Antonio Scala
CEO | Chief Executive Officer | 40 | 31/12/13 |
Giuseppe Somma
IRC | Investor Relations Contact | - | 30/06/19 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Marco Mazzarese
BRD | Director/Board Member | 46 | 31/12/18 |
Lucio Fusaro
BRD | Director/Board Member | 69 | 31/12/21 |
Umberto di Maio
FOU | Founder | 51 | 12/10/14 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 03/07/24 | 3.9 | 0.00% | 0 |
| 02/07/24 | 3.9 | -1.02% | 2,000 |
| 01/07/24 | 3.94 | 0.00% | 1,000 |
| 28/06/24 | 3.94 | +1.55% | 750 |
| 27/06/24 | 3.88 | 0.00% | 0 |
Real-time Borsa Italiana, July 03, 2024 at 04:44 pm
More quotes
Shedir Pharma Srl is an Italy-based pharmaceutical company specialized in nutraceuticals, cosmetics and medical devices. The Company markets its products in different forms and under the brand lines Shedir Farmaceutici, Deimos Farmaceutici, Phobos Farmaceutici, Menkar Farmaceutici and Greenplanet Divisione Farmaceutica. Its products cover a wide range of therapeutics areas, such as cardiovascular, dermatology, neurology, urology, gynecology and dental health, among others.
Sector
Pharmaceuticals
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -13.72% | 47.58M | |
| +54.07% | 816B | |
| +38.59% | 634B | |
| -7.05% | 351B | |
| +15.44% | 323B | |
| +5.72% | 293B | |
| +13.40% | 238B | |
| +0.61% | 222B | |
| +13.24% | 218B | |
| +7.42% | 167B |
- Stock Market
- Equities
- SHE Stock
